Dynavax Technologies Corporation

Dynavax Technologies — Q3 2025 Earnings Presentation

27 slides from Dynavax Technologies's earnings presentation, Nov 5, 2025

  1. Slide 1: Earnings Report Q3'25

    Earnings Report Q3’25 Using Proven, Innovative Adjuvant Technology to Help Protect the World Against Infectious Diseases November 2025 Nasdaq: DVAX

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained in this presentation regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements about Dynavax's financial results and market share as

  3. Slide 3: Executing on Our Strategy: Q3'25 Highlights

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Executing on Our Strategy: Q3’25 Highlights HEPLISAV-B® Quarterly Advancing Clinical Delivering Strong Sales Pipeline Milestones Financial Profile Net product revenue: Shingles vaccine program: Cash, cash equivalents an

  4. Slide 4: Our Core Strategic Priorities

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE OUR CORE STRATEGIC PRIORITIES Maximizing HEPLISAV-B’s Advancing Diversified Vaccine Continue Balanced Allocation of Commercial Potential Pipeline With CpG 1018® Adjuvant Capital to Accelerate Growth • Achieve at least 6

  5. Slide 5: Leveraging CpG 1018 Adjuvant Across Organic Pipeline

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Leveraging CpG 1018 Adjuvant Across Organic Pipeline Well-defined Mechanism of Action (MOA) & Clinical Profile pDC maturation T-cell activation Neutralization of pathogens and Proprietary CpG 1018 1 CpG 1018 CD28 pathog

  6. Slide 6: HEPLISAV-B Clinical Outcomes

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE HEPLISAV-B® Primary Endpoint Results: Study 2 per protocol population (ages 40-70)1, N=1,482 [Hepatitis B Vaccine (Recombinant), Adjuvanted] HEPLISAV-B Engerix-B Clinical Outcomes Primary endpoint Primary endpoint 100%

  7. Slide 7: Continued HEPLISAV-B Growth: Revenue & Market Share

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Continued HEPLISAV-B Growth: Revenue & Market Share HEPLISAV-B Vaccine Annual Net Product Revenue ($M)1 HEPLISAV-B Total U.S. Market Share2 Quarter End Trailing-12-Month (TTM) ~17-21% 50% 325 Anticipated 65% CAGR 2025 N

  8. Slide 8: HEPLISAV-B Market Opportunity Expected to Surpass $900M in U.S. by 2030

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE HEPLISAV-B Market Opportunity Expected to Surpass $900M in U.S. by 2030 Source: Internal data and company estimates. Not independently verified. 1Based on 2024 U.S. adult Hepatitis B vaccines net sales, adjusted for com

  9. Slide 9: HEPLISAV-B is the Market Share Leader in Retail Pharmacy

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE HEPLISAV-B is the Market Share Leader in Retail Pharmacy - the Largest Projected Growth Segment 2024 Market Size: ~$615M1 2030 Projected Market Size: >$900M2 Dialysis4 HEPLISAV-B Market Share 5% Dialysis4 Q3 2025 7% Mar

  10. Slide 10: Vaccine Development Pipeline

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Vaccine Development Pipeline IND- BLA Program enabling Phase 1 Phase 2 Phase 3 Review Partner Current Status & Planned Milestones Wholly • Presented positive top-line Part 1 Phase 1/2 trial results at IDWeek 2025 Shingl

  11. Slide 11: Shingles Vaccine Program: New Options Needed

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program New Options Needed Current Market-Leading Vaccine Associated with Adverse Events1 Herpes Zoster (shingles) is an extremely painful consequence of the Program Status: • Presented positive topline

  12. Slide 12: Phase 1/2 Study Design (Part 1)

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Phase 1/2 Study Design (Part 1) Safety, Tolerability, and Immunogenicity of Zoster-1018 Compared to Shingrix® • Randomized, active-controlled, dose- ENROLLED escalation trial N=441 R Randomizati

  13. Slide 13: Topline Immunogenicity Results Summary

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Topline Immunogenicity Results Summary1 Z-1018 demonstrated comparable immunogenicity to Shingrix Vaccine Response Rates (VRR)2 Anti-gE IgG Antibodies Activated gE-specific CD4+ T-cells Composit

  14. Slide 14: Topline Immunogenicity Results Summary (cont.)

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Topline Immunogenicity Results Summary1 (cont.) Z-1018 demonstrated comparable immunogenicity to Shingrix Anti-gE IgG Antibodies gE-specific CD4+ T-cells Geometric Mean Concentration Geometric M

  15. Slide 15: Topline Tolerability Results Summary

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Topline Tolerability Results Summary1 Tolerability Rate of Moderate/Severe Post Injection Reactions (PIRs)2 Local PIRs, (%) Systemic PIRs, (%) Z-1018 100 µg Z-1018 100 µg + alum Shingrix Z-1018

  16. Slide 16: Phase 1/2 Study Design (Part 2)

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Phase 1/2 Study Design (Part 2) Safety, Tolerability, and Immunogenicity of Zoster-1018 Compared to Shingrix® In Adults 70 years and Older • Randomized, active-controlled, multicenter ENROLLED s

  17. Slide 17: Path to Establishing Proof-of-Concept for a Differentiated Shingles Vaccine

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Shingles Vaccine Program Path to Establishing Proof-of-Concept for a Differentiated and Best-in-Class Shingles Vaccine Key Trial Objectives / Next Steps PHASE 1 CLINICAL TRIAL PHASE 1/2 CLINICAL TRIAL FUTURE DEVELOPMENT

  18. Slide 18: Additional Pipeline Programs

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Additional Pipeline Programs Plague Vaccine Pandemic Influenza Adjuvant Lyme Disease Vaccine Government agencies research and One of the most persistent and Bacterial infection that is the most stockpile vaccines as unp

  19. Slide 19: Exclusive License for Vaxart Oral Vaccine Program

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE COVID-19 Oral Vaccine Program Exclusive License for Vaxart Oral Vaccine Program Positioned to leverage Vaxart’s oral vaccine platform and Dynavax’s commercial experience Key Terms Transaction Rationale • Dynavax entered

  20. Slide 20: Best-in-Class Potential due to Novel Mechanism of Action

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE COVID-19 Oral Vaccine Program Best-in-Class Potential due to Novel Mechanism of Action and Differentiated Delivery Method Oral COVID-19 Vaccine Establishing a Differentiated Product Profile Opportunity: Oral administrat

  21. Slide 21: Potential to Transform the Multi-Billion-Dollar COVID-19 Vaccine Market

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE COVID-19 Oral Vaccine Program Potential to Transform the Multi-Billion-Dollar COVID-19 Vaccine Market Opportunity U.S. Annual Market Opportunity Unmet Need • Broad and durable variant protection—waning Continued public

  22. Slide 22: Financial Summary

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Financial Summary Q3’25 Financial Highlights Full Year 2025 Financial Guidance2 Financial Summary ($M) Q3’25 Q3’24 % Change HEPLISAV-B Net Revenue Total Revenues 94.9 80.6 18% HEPLISAV-B Net Product Revenue 90.0 79.3 13

  23. Slide 23: Our Capital Allocation Priorities

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Creating Value through Disciplined and Balanced Capital Allocation Strategy OUR CAPITAL ALLOCATION PRIORITIES 1 2 3 4 Maximizing Investing in Accessing late- Opportunistically HEPLISAV-B pipeline leveraging stage assets

  24. Slide 24: Executing on Our Strategy: Q3'25 Highlights

    CORPORATE UPDATES COMMERCIAL: HEPLISAV-B CLINICAL & PRECLINICAL PIPELINE FINANCE Executing on Our Strategy: Q3’25 Highlights HEPLISAV-B® Quarterly Advancing Clinical Delivering Strong Sales Pipeline Milestones Financial Profile Net product revenue: Shingles vaccine program: Cash, cash equivalents an

  25. Slide 25: Thank you

    Thank you August 2025 Nasdaq: DVAX

  26. Slide 26: Non-GAAP Financial Measures

    Non-GAAP Financial Measures To supplement our financial results presented on a GAAP basis, we have included information about Adjusted EBITDA, a non-GAAP financial measure. We believe the presentation of this non-GAAP financial measure, when viewed with our results under GAAP and the accompanying re

  27. Slide 27: Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA

    Dynavax Technologies Corporation Reconciliation of GAAP Net Income (Loss) to Adjusted EBITDA (In Thousands) (Unaudited) Three Months Ended Nine Months Ended September 30, September 30, 2025 2024 2025 2024 GAAP net income (loss) $26,927 $17,594 $(50,451) $20,259 Adjustments: Depreciation & amortizati

Dynavax Technologies — Q3 2025 Earnings Presentation on 6ix